Nanotechnology-related Drug Database Nakissa Sadrieh, Ph.D. - - PowerPoint PPT Presentation

nanotechnology related drug
SMART_READER_LITE
LIVE PREVIEW

Nanotechnology-related Drug Database Nakissa Sadrieh, Ph.D. - - PowerPoint PPT Presentation

Overview of CDER Nanotechnology-related Drug Database Nakissa Sadrieh, Ph.D. Director, Cosmetics Staff, OCAC/CFSAN/FDA (Previously, Associate Director for Research Policy and Implementation, OPS/CDER/FDA) FDA/PQRI workshop 2014 1 What has


slide-1
SLIDE 1

1

Overview of CDER Nanotechnology-related Drug Database

Nakissa Sadrieh, Ph.D.

Director, Cosmetics Staff, OCAC/CFSAN/FDA

(Previously, Associate Director for Research Policy and Implementation, OPS/CDER/FDA)

FDA/PQRI workshop 2014

slide-2
SLIDE 2

What has been the impact of nanotechnology-containing drugs on CDER applications?

– How can CDER evaluate product attributes which might describe nanotechnology-related drugs?

  • FDA guidance document
  • CDER MAPP

– Which drug products might possess aspects of nanotechnology-related characteristics?

  • CDER database of nanotechnology-related products

– How can CDER help address the data gaps?

  • Research

2

slide-3
SLIDE 3

Outline

  • What product attributes describe nanotechnology-related

properties?

– CDER MAPP

  • Which drug products might possess aspects of

nanotechnology-related characteristics?

– CDER nanotechnology drug database

  • How can CDER help address existing data gaps?

– Dermal penetration of nanoscale TiO2 in sunscreens. – Development of discriminating dissolution methods for nanocrystals with different particle sizes. – Inhalation toxicology of spray sunscreens and cosmetics.

3

slide-4
SLIDE 4

4

CDER Manual of Policies and Procedures for Drugs Containing Nanomaterials

  • CDER MAPP: “Reporting format for nanotechnology-

related information in CMC reviews” (June 2010)

  • Purpose of the MAPP:

– To collect in CDER CMC reviews, data submitted on nanotechnology-related information.

  • Criteria used for data collection:

– If the particle size of the product is reported in the submission as being under 1000 nm, then the CMC review should contain a table included in the MAPP.

slide-5
SLIDE 5

5 Nanotechnology Product MaPP Attachment A

1) This review contains new information added to the table below: _______Yes _______No Review date: _____________ 2) Are any nanoscale materials included in this application? (If yes, please proceed to the next questions.) Yes______; No______ ; Maybe (please specify)____________________ 3 a) What nanomaterial is included in the product? (please refer to attachment B for examples of nanomaterial)_______________________________________________________________ 2 b) What is the source of the nanomaterial?________________________________________ 4) Is the nanomaterial a reformulation of a previously approved product? Yes_________ No_________ 5) What is the nanomaterial functionality? Carrier_________________; Excipient__________________; Packaging________________ API____________________; Other____________________ ____________________________________________________________________________ 6) Is the nanomaterial soluble (e.g., nanocrystal) or insoluble (e.g., gold nanoparticle) in an aqueous environment? Soluble __________________; Insoluble___________________ 7) Was nanomaterial particle size or size range included in the application? No_______(please go to 9); Yes________ (please complete 8). 8) What is the reported particle size? Mean particle size___________ ; Size range distribution___________; Other___________________, 9) Please indicate the reason(s) why the particle size or size range was not provided: ____________________________ ____________________________ 10) What other properties of the nanoparticle were reported in the application (See Attachment E)? ____________________________ 11) List all methods used to characterize the nanomaterial? ___________________________

slide-6
SLIDE 6

6

Evaluation of CDER Nanotechnology Database

  • Drugs that use nanotechnology include:

– New molecular entities formulated with components in the nanoscale. – Reformulations of already approved products:

  • a decrease in the particle size may change some

aspect of the drug (such as targeted drug delivery, pharmacokinetic profile, a more convenient dosage form thus better patient compliance).

  • Typical platforms include, but are not limited to:

– Liposomes, nanocrystals, nanoemulsions, dendrimers, metal oxides (superparamagnetic iron

  • xide, titanium dioxide, zinc oxide), gold and silver

nanoparticles.

slide-7
SLIDE 7

7

Nanotechnology-related Submissions

52 39 14 9 6 4 3 1 128 10 4 8 2 5 1 30 20 40 60 80 100 120 140 L i p

  • s
  • m

e s ( 6 2 ) N a n

  • p

a r t i c l e s ( 4 3 ) N a n

  • c

r y s t a l s ( 2 2 ) M i c e l l e s ( 1 1 ) S P I O ( 1 1 ) N a n

  • e

m u l s i

  • n

s ( 5 ) C

  • l

l

  • i

d a l m e t a l s ( 3 ) D e n d r i m e r ( 1 ) A l l ( 1 5 8 ) # of Submissions IND applications

slide-8
SLIDE 8

8

Nanotechnology-related Platforms

Liposomes 39.2% Nanoparticles 27.2% Nanocrystals 13.9% Micelles 7.0% SPIO 7.0% Nanoemulsions 3.2% Colloidal metals 1.9% Dendrimer 0.6%

slide-9
SLIDE 9

9

Indications

Cancer 38.0% Pain 10.1% Infection 8.9% MRI 5.7% Immunosupp 4.4% Diabetes 3.8% Anemia 3.8% Cholesterol 3.2% Others 22.2%

slide-10
SLIDE 10

10

Routes of Administration

68 51 9 73 91 40 33 1 00 56 1 8 5 9 9 1 8 28 82 9 33 23 7 9 60 4 6 9 9 33 6

20 40 60 80 100 Liposomes (62) Nanoparticles (43) Nanocrystals (22) Micelles (11) SPIO (11) Nanoemulsions (5) Colloidal metals (3) Dendrimer (1) All (158) % Submissions IV Inhalation

  • ral

topical

  • ther inj
slide-11
SLIDE 11

11

Characterization

  • Many parameters may require characterization.
  • But size specification of nanoparticles in bulk

material and formulated drug product are important in understanding a drug’s PK and PD profile.

  • Size can be reported differently (mean or

distribution).

  • Different size measurement methodologies can

have varying degrees of limitations.

slide-12
SLIDE 12

12

Multiple Parameters…. Multiple Techniques

slide-13
SLIDE 13

13

Particle Size Formats Reported in CDER Submissions

1 2 1 9 7 5 4 1 48 35 1 6 6 6 6 4 2 1 76 8 2 1 1 1 2 7 1 1 1 1 29 3 3

10 20 30 40 50 60 70 80 L i p

  • s
  • m

e s ( 6 5 ) N a n

  • p

a r t i c l e ( 4 7 ) N a n

  • c

r y s t a l s ( 2 4 ) M i c e l l e ( 1 2 ) S P I O ( 1 1 ) N a n

  • e

m u l s i

  • n

s ( 5 ) C

  • l

l

  • i

d a l m e t a l s ( 3 ) D e n d r i m e r ( 1 ) A l l ( 1 6 8 ) # of Submissions Mean Mean range Mean +/- STD Cumulative Not available

slide-14
SLIDE 14

14

Assumptions Used In Analysis Of CDER Database

  • Our analysis considered only one value for the mean,

assuming that all measures of mean values were equivalent:

– Mean, mean range, mean+/-SD, median

  • Our analysis did not consider that different methods

used to assess mean values (such as DLS, TEM, FFF, etc…) would introduce different degrees of variability, because of fundamental differences in the methods.

  • Our analysis did not take into account inherent

differences in formulations (e.g. suspensions versus powder) that would be impacted by the particle size measurement methodologies.

slide-15
SLIDE 15

15

Percentage of Submissions With Some Form of “Mean Particle Size” Information

98% 2% Size available (155) Size not available (3)

slide-16
SLIDE 16

16

Particle Size Methodologies Used in Nanotechnology-Related Submissions

Dynamic light scattering 24% Laser diffraction 10% Microscopy 6% Cascade Impactor 3%

  • thers

2% NA 55%

slide-17
SLIDE 17

17

Reported “Mean” Particle Size For All Nanotechnology-related Submissions

35 29 8 26 2 10 20 30 40 50 60

<100 (56) 100 - 300 (46) 300 - 600 (12) 600 - 1000 (0) >1000 (41) NA (3) nm % Submissions

slide-18
SLIDE 18

18

Reported “Mean” Particle Size For Nanotechnology- related Submissions Under 1000 nm

49 40 11 10 20 30 40 50 60

<100 (56) 100 - 300 (46) 300 - 600 (12) 600 - 1000 (0) nm % Submissions

slide-19
SLIDE 19

19

Distribution of “Mean” Particle Size in CDER Database

100 200 300 400 500 600 700 1 2 3 4 5 6 7 8 nm

Liposomes Nanoparticles Nanocrystals Micelles SPIO Nanoemulsions Colloidal Metals

slide-20
SLIDE 20

Examples of Biological Responses Subject To Size Limitations

Biological responses Size limits Comments

Glomerular filtration 5-10 nm Physiologic upper limit by renal clearance Nanoparticles transport through liver sinusoid 300 nm Liver fenestrae act as a sieve plate and can control the passage of nanoparticles, allowing only those particles smaller than the fenestrae to reach the liver cells. Size distribution of sinusoidal fenestrae among different species; 75 - 300 nm in rats, 45 - 255 nm in rabbits, 55 - 320 nm in mice and 50 - 300 in humans. Particle shapes and rigidity may further affect the size limit, for example, liposome sizes of up to 400 nm were able to cross the liver fenestrae. Enhanced permeability and retention (EPR) 300-600 nm EPR effects may vary depending on the species, tumor implantation sites and tumor

  • types. Pore size may also be different in xenografts than in natural tumors. Nanoscale

particles up to 300 nm in diameter extravasate through leaky tumor vasculature and selectively accumulate in tumor tissue via EPR effect. In study involving liposomes, sizes up to 600 nm in diameter were able to permeate through the tissues. Thus, average pore sizes may be approximately assumed in 300 - 600 nm range. Reticuloendothelial system (RES) uptake 300 nm Nanoparticles are cleared by size dependent phagocytosis by the cells in reticuloendothelial system. Extended blood residence time for surface modified nanoparticles up to 200 – 300 nm.

slide-21
SLIDE 21

Completed SRS Research to Address Regulatory Science Questions

  • Dermal penetration studies in pigs, using

formulated sunscreens containing nanoparticles

  • f TiO2.
  • Evaluation of the impact of particle size, on the

dissolution and bioavailability of poorly soluble nanocrystalline drugs (such as Naproxen).

21

slide-22
SLIDE 22

Ongoing and Planned Research Studies with Nanotechnology-Related Products

  • FDA funded research project (CORES 2013) on

the inhalation toxicity of spray sunscreens containing TiO2. collaboration with NIST, NIOSH, NCTR, CDER.

  • Proposed FDA funded research project on the

inhalation toxicity of spray cosmetics and mineral powders containing TiO2, ZnO and

  • ther potential nanoparticles.

22

slide-23
SLIDE 23

Study Procedures

  • Characterization studies at NCTR and NIST to evaluate
  • f selected products have nanoparticles, and to

characterize particle size.

  • In vivo inhalation toxicology studies at NIOSH (The spray

generation and animal exposure systems will be similar to those described in McKinney et al., Inhal. Toxicol. 24:447-457, 2012).

23

slide-24
SLIDE 24

24

Summary

  • The Science and Research Staff (SRS) has

done a preliminary analysis of nanotechnology- related drugs submitted for review.

  • The SRS has completed a number of research

projects to address regulatory gaps associated with the use of nanoparticles in drug products.

  • There are ongoing research projects to address

current regulatory gaps associated with the use

  • f nanoparticles in FDA-regulated products.